← Back to Screener
Biomea Fusion, Inc. Common Stock (BMEA)
Price$1.39
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)22.07%
Price vs S&P 500 (4W)-4.24%
VGM Score45.89
Market Capitalization$99.77M
All Metrics
Book Value / Share (Quarterly)$0.26
P/TBV (Annual)3.45x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.78
Price vs S&P 500 (YTD)0.36%
EPS (TTM)$-0.89
10-Day Avg Trading Volume1.10M
EPS Excl Extra (TTM)$-0.89
EPS (Annual)$-1.18
ROI (Annual)-209.11%
Cash / Share (Quarterly)$0.62
ROA (Last FY)-105.51%
EBITD / Share (TTM)$-1.07
ROE (5Y Avg)-129.09%
Cash Flow / Share (Annual)$-0.97
P/B Ratio5.33x
P/B Ratio (Quarterly)5.91x
Net Income / Employee (Annual)$-1,507,200
ROA (TTM)-77.07%
EPS Incl Extra (Annual)$-1.18
Current Ratio (Annual)5.23x
Quick Ratio (Quarterly)4.85x
3-Month Avg Trading Volume1.36M
52-Week Price Return-7.38%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$5.59
52-Week High$3.08
EPS Excl Extra (Annual)$-1.18
26-Week Price Return38.00%
Quick Ratio (Annual)5.03x
13-Week Price Return-4.83%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.98x
Enterprise Value$55.08M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.77
3-Month Return Std Dev100.47%
Net Income / Employee (TTM)$-1,096,300
ROE (Last FY)-209.11%
EPS Basic Excl Extra (Annual)$-1.18
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.89
ROI (TTM)-196.72%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.67
Price vs S&P 500 (52W)-35.59%
Year-to-Date Return11.29%
5-Day Price Return-2.82%
EPS Normalized (Annual)$-1.18
ROA (5Y Avg)-84.60%
Month-to-Date Return1.47%
Cash Flow / Share (TTM)$-3.27
EBITD / Share (Annual)$-1.57
ROI (5Y Avg)-129.09%
EPS Basic Excl Extra (TTM)$-0.89
P/TBV (Quarterly)1.87x
P/B Ratio (Annual)2.97x
Book Value / Share (Annual)$0.41
Price vs S&P 500 (13W)-14.57%
Beta-0.33x
Revenue / Share (TTM)$0.00
ROE (TTM)-196.72%
52-Week Low$0.87
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.17est. -0.24
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.15
4.15
4.15
4.15
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BMEABiomea Fusion, Inc. Common Stock | — | — | C | $1.39 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Biomea Fusion is a clinical-stage biopharmaceutical company developing oral small-molecule therapies for diabetes and obesity. Its lead candidate, icovamenib, is a covalent menin inhibitor in clinical trials for type 1 and type 2 diabetes and obesity, while BMF-650, an oral GLP-1 receptor agonist, is in development for the same indications. The company leverages its proprietary FUSION System platform to discover novel drug candidates targeting metabolic diseases.